Suoyuan bio positioning precision medical guidance clinical "waste" innovative drug research and development and regeneration

Suoyuan biological company, a subsidiary of Xianju pharmaceutical, said at the strategic meeting of securities companies that the company positioned precision medicine, guided the research and development and regeneration of clinical "abandoned" innovative drugs through unique biomarker platform technology, and realized the reconstruction of value from zero to one billion through this "pioneering" business model According to the person, the company introduced new drugs from large international pharmaceutical plants that have been proved safe and effective for some patients through phase II and phase III clinical trials, and used its unique and exclusive biomarker platform technology to screen patients, so as to achieve the purpose of personalized medical treatment "The safety of the above innovative drugs with failed R & D has been verified in multiple clinical trials of the original research party The clinical development guided by biomarkers can obtain the value reconstruction of drugs with less investment and lower risk." He also pointed out that the company's competitive advantage in carrying out this business is mainly reflected in the fact that the company has a high technical threshold with the patent technology of reverse full gene scanning At the same time, the company has good business cooperation with large international pharmaceutical companies, including Lilly, and has successful application cases in anti lung cancer drugs According to Haitong Securities Research Report, in addition to the limaglume TAD methionil, Suoyuan biology also obtained the global authorization of the phase III anti-tumor drug enzastaurin from lilly on September 16, 2014, and a phase III advanced lung cancer drug (db101) before In addition to the above products, the company has more than 150 drug candidates, the company said Xianju pharmaceutical is mainly engaged in the pharmaceutical industry Its products mainly include corticosteroids, gynecological and family planning drugs, anesthetics and muscle relaxants The company holds 30% equity of Suoyuan bio